Performed in a single session without any surgical incisions or scarring, the treatment utilizes an advanced fusion-guided ...

But an association with improved overall survival failed to reach statistical significance ...

In February 2026, Bayer filed a lawsuit in U.S. federal court accusing Johnson & Johnson and Janssen Biotech of falsely ...

The main market opportunities lie in the commercialization and development of PSMA-targeted therapies and radiodiagnostics for prostate cancer. Key areas include expansion in radioligand therapy and ...

Astellas Pharma Inc. and Vir Biotechnology, Inc. have entered into a global strategic collaboration to advance VIR-5500, an ...

When PSA rises after surgery, PSMA PET/CT detects cancer missed by conventional imaging ...

For the last three years, Bayer has been implementing a new strategy for its oncology development, a strategy that led to multiple approvals, as well as a number of promising new programmes added to ...

Long-used imaging strategies such as computed tomography (CT) and bone scintigraphy (BS) to detect lymph node and bone metastases have significant limitations and disadvantages. Newly emerging ...

Frontiers in Oncology publication positions metabo-oncology as a differentiated platform for pharma and a novel, ...

As RLTs and theranostics gain prevalence, companies must consider how to overcome their associated regulatory, manufacturing ...

NEW HAVEN, Conn.--(BUSINESS WIRE)--Halda Therapeutics, a clinical-stage biotechnology company developing a novel class of cancer therapies called RIPTAC™ (Regulated Induced Proximity TArgeting ...